stonks4u
Sign up free
PRGO logo

PRGO Perrigo Company plc

New York Stock Exchange · Drug Manufacturers - Specialty & Generic · Healthcare

$13.04
+0.21 (+1.64%)

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral…

Market Cap: $1.80Bwww.perrigo.com

Price (90d)

$12.84
$9.49$10.75$12.01$13.27
May 1Aug 7

Signal Score (90d)

119
105110114119
Aug 8Aug 13

Quote

Day Range
$12.61 – $13.05
52-Week Range
$9.23 – $24.61
Volume
$1.59M
Market Cap
$1.80B
50-Day Avg
$10.84
200-Day Avg
$12.40
Prev Close
$12.83
Open
$12.72

Valuation & Ratios

P/E Ratio
-1.35
EPS
$-10.29
P/B Ratio
0.66
P/S Ratio
0.45
Debt/Equity
1.35
Current Ratio
2.76
Dividend Yield
+8.3%
Gross Margin
+35.1%

Returns & Efficiency

Return on Equity
-48.6%
Return on Assets
-16.7%
FCF Yield
+7.5%
EV/EBITDA
-6.72

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$4.25B$-1.43B$-10.29
2024$4.37B$-171.80M$-1.25
2023$4.66B$-12.70M$-0.09
2022$4.45B$-140.60M$-0.97
2021$4.14B$-68.90M$-0.98

Social Signal Score

65
5d
69
1 mentions
+0.0%
30d
64
3 mentions
+15.1%
60d
64
3 mentions
+20.3%
90d
64
3 mentions
+21.0%
news: 3

Earnings

Wed, Nov 4(in 3 months)

Consensus estimate $0.52 per share

5of 7 quarters beat consensus

Typical surprise +6.7% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 5$0.50 vs $0.39beat
  • Wed, May 6$0.43 vs $0.39beat
  • Thu, Feb 26$0.77 vs $0.80miss
  • Wed, Nov 5$0.80 vs $0.75beat
  • Wed, Aug 6$0.57 vs $0.59miss
  • Wed, May 7$0.60 vs $0.56beat

Estimates and results for PRGO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

PRGOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsseekingalpha.com·2d ago·Positive

    Perrigo: The Rebound Is Just Getting Started Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.

    View source ↗
  • Newszacks.com·5d ago·Positive

    PRGO vs. NEOG: Which Stock Is the Better Value Option? Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?

    View source ↗
  • Newsmarketbeat.com·6d ago·Neutral

    Perrigo Q2 Earnings Call Highlights Perrigo NYSE: PRGO reported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving category trends, market-share gains and expected second-half contributions from innovation, distribution and demand-generation efforts.

    View source ↗